SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals Solutions for RSV Vaccine Trials

OPTIMIZING RSV VACCINE TRIALS FOR A HEALTHIER TOMORROW

Vaccine trials pose unique challenges. Sponsors need partners well-versed in each disease indication who can handle large-scale, multi-phase international studies, meet critical milestones, support long-term patient follow-up periods, and facilitate critical data management tasks.

That's why dozens of sponsors and CROs trust Signant to help navigate these complexities and capture the audit-ready, high-quality evidence required to get new vaccines to patients in need.

SIGNANT SMARTSIGNALS® SOLUTIONS FOR RSV TRIALS

eCOA

Use our built-in reactogenicity diary instrument on either provisioned or bring-your-own devices to collect high quality primary safety data. Flexible implementation options, built-in alerts that keep PROs on track, and data management services are just some of the features that make our eCOA solution ideal for vaccine studies.

RTSM

Optimize study supply management and efficiently manage mid-study changes using adaptable randomization and distribution schemes as well as our global logistics team that can handle any product's time or temperature requirements.

eCONSENT

Obtain fast and traceable consent, assent, and reconsent with our rapid, simple, eConsent solution.

TELEMEDICINE

Connect patients to study teams remotely to improve safety and reduce unnecessary site visits.

PATIENT CONCIERGE

Keep participants engaged during long follow-up periods, encouraging study requirements adherence and participant retention.

LARGE-SCALE VACCINE TRIAL CASE STUDY

When Pfizer requested our services for a rapidly implemented phase I/II/III COVID-19 vaccine trial, Signant was ready. We facilitated the launch of a 45,000-participant, global vaccine study involving 150 sites in seven countries - in just five weeks. Signant was the only partner prepared with the solutions, global reach, and resources to meet the protocol's challenges, helping the sponsor achieve full regulatory approval for a novel vaccine in record time.

45,000 PATIENTS BYOD & PROVISIONED DEVICES

150 SITES

5 WEEKS eCOA STUDY DESIGN TO LAUNCH

7 COUNTRIES

SIGNANT'S RSV VACCINE EXPERIENCE

37
STUDIES

80,500+
PATIENTS
(PEDIATRIC, ADULT, GERIATRIC)

37
COUNTRIES

3,200+
SITES

PHASES
I-III
VALIDATION

40
LANGUAGES

READY TO DISCUSS YOUR PROTOCOL?

CONNECT WITH US

WHO IS SIGNANT HEALTH?

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.

SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™